ClinicalTrials.gg

Program

luxdegalutamide

Also written as “JSB462 Dose 1 QD”, “JSB462 Dose 2 QD” and “JSB462 QD”.

In Novartis’s pipeline, Androgen receptor protein degrader. Its studies are mostly in Prostatic Neoplasms, led by Novartis.

Furthest: phase 2, since Sep 23, 20212 company-led studies, 2 open or runningNext primary completion: May 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis22 open or runningphase 2since Sep 23, 2021Sep 23, 2021May 25, 2027phase 2 · NCT05067140
  • Named in Novartis’s own pipeline as JSB462 (luxdegalutamide), phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 23, 2021First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT05067140 · 164 enrolled · United States
  2. Sep 17, 2025Phase 2 study in Progressive Metastatic Castrate Resistant Prostate CancerNCT07206056 · 188 planned · United States, Australia, Canada and more

Ahead

  1. May 25, 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT05067140
  2. Nov 9, 2029Primary completion: phase 2 study in Progressive Metastatic Castrate Resistant Prostate CancerNCT07206056

TargetBeta

“Androgen receptor protein degrader”the company's pipeline, read by Claude · source
“An orally bioavailable androgen receptor (AR)-targeted protein degrader, composed of an AR ligand ”NCIt, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer · United States, Australia, Canada and more2RecruitingNov 9, 2029188
NCT05067140Prostatic Neoplasms · United States2Active, not recruitingMay 25, 2027164

How it is read

Names in the registry

  • “JSB462 Dose 1 QD”, 1 entry
  • “JSB462 Dose 2 QD”, 1 entry
  • “JSB462 QD”, 1 entry
  • “ARV-766”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.